Yisheng Jiang

Yisheng Jiang

Auto-generated profile, based on publicly available information

Yisheng Jiang

State Key Laboratory of Molecular Developmental Biology, CAS Center for Excellence in Brain Science and Intelligence Technology, Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2021 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
HPHuanhuan Pang
Huanhuan Pang
YJYisheng Jiang
Yisheng Jiang
JLJie Li
Jie Li
YWYushen Wang
Yushen Wang
MNMeng Nie
Meng Nie
ZHZeping Hu
Zeping Hu

29 April 2022 in Cell Discovery
Verified
Journal Article
Open access
PDF file
YJYisheng Jiang
Yisheng Jiang
YDYongqiang Deng
Yongqiang Deng
HPHuanhuan Pang
Huanhuan Pang
TMTiantian Ma
Tiantian Ma
QYQing Ye
Qing Ye
ZXZhiheng Xu
Zhiheng Xu
The global COVID-19 epidemic has spread rapidly around the world and caused the death of more than 5 million people. It is urgent to develop effective strategies to treat COVID-19 patients. Here, we revealed that SARS-CoV-2 infection resulted in the dysregulation of genes associated with NAD+ metabolism, immune response, and cell death in mice, similar to that in COVID-19 patients. We therefore investigated the effect of treatment with NAD+ and its intermediate (NMN) and found that the pneumonia phenotypes, including excessive inflammatory cell infiltration, hemolysis, and embolization in SARS-CoV-2-infected lungs were significantly rescued. Cell death was suppressed substantially by NAD+ and NMN supplementation. More strikingly, NMN supplementation can protect 30% of aged mice infected with the lethal mouse-adapted SARS-CoV-2 from death. Mechanically, we found that NAD+ or NMN supplementation partially rescued the disturbed gene expression and metabolism caused by SARS-CoV-2 infection. Thus, our in vivo mouse study supports trials for treating COVID-19 patients by targeting the NAD+ pathway.

1 May 2018 in Cell Reports
Verified
Journal Article
Open access
CLCui Li
Cui Li
FGFei Gao
Fei Gao
LYLei Yu
Lei Yu
RWRuoke Wang
Ruoke Wang
YJYisheng Jiang
Yisheng Jiang
Linqi ZhangLinqi Zhang
Linqi Zhang
Zika virus (ZIKV) is a mosquito-transmitted flavivirus that is generally benign in humans. However, an emergent strain of ZIKV has become widespread, causing severe pre- and post-natal neurological defects. There is now an urgent need for prophylactic and therapeutic agents. To address this, we investigated six human monoclonal antibodies with ZIKV epitope specificity and neutralizing activity in mouse models of ZIKV infection and microcephaly. A single intraperitoneal injection of these antibodies conveyed distinct levels of adult and in utero protection from ZIKV infection, which closely mirrored their respective in vitro neutralizing activities. One antibody, ZK2B10, showed the most potent neutralization activity, completely protected uninfected mice, and markedly reduced tissue pathology in infected mice. Thus, ZK2B10 is a promising candidate for the development of antibody-based interventions and informs the rational design of ZIKV vaccine.

6 January 2021 in Genomics, Proteomics & Bioinformatics
Verified
Journal Article
Open access
YCYafei Chang
Yafei Chang
YJYisheng Jiang
Yisheng Jiang
CLCui Li
Cui Li
QWQin Wang
Qin Wang
FZFeng Zhang
Feng Zhang
ZXZhiheng Xu
Zhiheng Xu
The association of Zika virus (ZIKV) infection with microcephaly has raised alarm worldwide. Their causal link has been confirmed in different animal models infected by ZIKV. However, the molecular mechanisms underlying ZIKV pathogenesis are far from clear. Hence, we performed global gene expression analysis of ZIKV-infected mouse brains to unveil the biological and molecular networks underpinning microcephaly. We found significant dysregulation of the sub-networks associated with brain development, immune response, cell death, microglial cell activation, and autophagy amongst others. We provided detailed analysis of the related complicated gene networks and the links between them. Additionally, we analyzed the signaling pathways that were likely to be involved. This report provides systemic insights into not only the pathogenesis, but also a path to the development of prophylactic and therapeutic strategies against ZIKV infection.

2 September 2025 in Cell Research
Verified
Journal Article
Open access
PDF file
YJYisheng Jiang
Yisheng Jiang
FZFeipeng Zhu
Feipeng Zhu
JZJie Zhong
Jie Zhong
XSXiaomei Sun
Xiaomei Sun
YYYuting Yuan
Yuting Yuan
ZXZhiheng Xu
Zhiheng Xu
The brain’s hemispheres exhibit profound lateralization, yet the underlying mechanisms remain elusive. Using proteomic and phosphoproteomic analyses of the bilateral striatum — a hub for important brain functions and a common node of autism pathophysiology — we identified significant phosphorylation asymmetries. Particularly, the phosphorylation processes in the left striatum appear more prone to disturbance. Notably, SH3RF2, whose single-copy knockout leads to autism spectrum disorder (ASD)-like behaviors in mice, is uniquely expressed in the striatum, forming a complex with CaMKII (an ASD-associated protein) and PPP1CC. Loss of SH3RF2 disturbs the CaMKII/PP1 “switch”, resulting in hyperactivity of CaMKII and increased phosphorylation of its substrate GluR1. In Sh3rf2-deficient mice, heightened GluR1-Ser831 phosphorylation and its aberrant postsynaptic membrane localization in the left striatum may impair the functional lateralization of striatal neurons and contribute to autism-like behaviors. This study unveils the first molecular mechanism governing brain lateralization in mammals, linking its impairment to autism development and treatment strategies.

25 November 2025 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
YYYuting Yuan
Yuting Yuan
YLYang Li
Yang Li
FYFuqiang Yang
Fuqiang Yang
YJYisheng Jiang
Yisheng Jiang
YDYuanyuan Ding
Yuanyuan Ding
ZXZhiheng Xu
Zhiheng Xu
Autism spectrum disorder (ASD) is a prevalent and complex neurodevelopmental disorder with a strong genetic basis. Although SH3RF3 has been identified as an ASD candidate gene, its biological function and pathophysiological mechanisms remain elusive. Here, we reveal that SH3RF3 functions as an essential scaffold protein that facilitates presynaptic vesicle docking. Mechanistically, it orchestrates the formation of a molecular complex between the kinase BRSK1/SAD-B and the ASD-associated active zone protein RIM1. Genetic ablation of Sh3rf3 disrupts this protein-protein interaction, leading to reduced RIM1 phosphorylation. This perturbation triggers synaptic dysfunctions, marked by a substantial reduction in both total synaptic vesicle (SV) density and readily releasable pool size, coupled with delayed SV replenishment kinetics. These deficits ultimately impair excitatory synaptic transmission in the prefrontal cortex, disturb the excitatory-inhibitory (E/I) balance, and elicit autistic-like behaviors in mice. Notably, prefrontal cortex-specific restoration of Sh3rf3 reverses behavioral and functional deficits in knockout mice. Furthermore, our characterization of the SH3RF3 interactome reveals a shared molecular network encompassing ASD-risk genes, indicating that synapse-targeted therapies may have broad applicability.